메뉴 건너뛰기




Volumn 12, Issue 8, 2012, Pages 1077-1086

Statement of Retraction: Gantenerumab for the treatment of Alzheimer's disease (Expert Opinion on Biological Therapy, (2012), 12, 8, (1077-1086), 10.1517/14712598.2012.688022);Gantenerumab for the treatment of Alzheimer's disease

Author keywords

Alzheimer's disease; amyloid ; gantenerumab; immunotherapy; monoclonal antibody; amyloid peptide

Indexed keywords

AMYLOID BETA PROTEIN; BAPINEUZUMAB; ELN 115727; GANTENERUMAB; PLACEBO; PONEZUMAB; SAR 228810; SOLANEZUMAB; UNCLASSIFIED DRUG;

EID: 84863803152     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2021.2001186     Document Type: Erratum
Times cited : (31)

References (43)
  • 1
    • 72049130805 scopus 로고    scopus 로고
    • Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
    • Jack CR Jr, Knopman D, Jagust W, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28
    • (2010) Lancet Neurol. , vol.9 , pp. 119-128
    • Jack Jr., C.R.1    Knopman, D.2    Jagust, W.3
  • 2
    • 0028169925 scopus 로고
    • Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42 43
    • Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53
    • (1994) Neuron , Issue.13 , pp. 45-53
    • Iwatsubo, T.1    Odaka, A.2    Suzuki, N.3
  • 3
    • 84655162704 scopus 로고    scopus 로고
    • Soluble Abeta oligomer production and toxicity
    • Larson ME, Lesne SE. Soluble Abeta oligomer production and toxicity. J Neurochem 2012;120(Suppl 1):125-39
    • (2012) J. Neurochem. , vol.120 , Issue.SUPPL.1 , pp. 125-139
    • Larson, M.E.1    Lesne, S.E.2
  • 4
    • 84880189986 scopus 로고    scopus 로고
    • Immunotherapy for Alzheimer's disease
    • Morgan D. Immunotherapy for Alzheimer's disease. J Alzheimers Dis 2006;9:425-32
    • (2006) J. Alzheimers Dis. , vol.9 , pp. 425-432
    • Morgan, D.1
  • 5
    • 79959670013 scopus 로고    scopus 로고
    • The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects
    • Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011;31:9323-31
    • (2011) J. Neurosci. , vol.31 , pp. 9323-9331
    • Wiessner, C.1    Wiederhold, K.H.2    Tissot, A.C.3
  • 6
    • 77956206153 scopus 로고    scopus 로고
    • Vaccination therapy for Alzheimer's disease
    • Tabira T. Vaccination therapy for Alzheimer's disease. Rinsho Shinkeigaku 2009;49:848-50
    • (2009) Rinsho Shinkeigaku , vol.49 , pp. 848-850
    • Tabira, T.1
  • 7
    • 0033536163 scopus 로고    scopus 로고
    • Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
    • Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7
    • (1999) Nature , vol.400 , pp. 173-177
    • Schenk, D.1    Barbour, R.2    Dunn, W.3
  • 8
    • 0034700471 scopus 로고    scopus 로고
    • A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
    • Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-82
    • (2000) Nature , vol.408 , pp. 979-982
    • Janus, C.1    Pearson, J.2    McLaurin, J.3
  • 9
    • 0035106780 scopus 로고    scopus 로고
    • Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy
    • Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001;7:369-72
    • (2001) Nat. Med. , vol.7 , pp. 369-372
    • Bacskai, B.J.1    Kajdasz, S.T.2    Christie, R.H.3
  • 16
    • 73349091534 scopus 로고    scopus 로고
    • A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
    • Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70
    • (2009) Neurology , vol.73 , pp. 2061-2070
    • Salloway, S.1    Sperling, R.2    Gilman, S.3
  • 17
    • 77949300796 scopus 로고    scopus 로고
    • 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study
    • Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72
    • (2010) Lancet Neurol. , vol.9 , pp. 363-372
    • Rinne, J.O.1    Brooks, D.J.2    Rossor, M.N.3
  • 18
    • 77951086901 scopus 로고    scopus 로고
    • Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
    • Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33:67-73
    • (2010) Clin. Neuropharmacol. , vol.33 , pp. 67-73
    • Siemers, E.R.1    Friedrich, S.2    Dean, R.A.3
  • 19
    • 84862777153 scopus 로고    scopus 로고
    • Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis
    • Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol 2012;11:241-9
    • (2012) Lancet Neurol. , Issue.11 , pp. 241-249
    • Sperling, R.1    Salloway, S.2    Brooks, D.J.3
  • 20
    • 58149129243 scopus 로고    scopus 로고
    • Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain
    • Boche D, Zotova E, Weller RO, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008;131:3299-310
    • (2008) Brain , vol.131 , pp. 3299-3310
    • Boche, D.1    Zotova, E.2    Weller, R.O.3
  • 21
    • 65649148265 scopus 로고    scopus 로고
    • Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice
    • Wilcock DM, Colton CA. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets 2009;8:50-64
    • (2009) CNS Neurol Disord Drug Targets , vol.8 , pp. 50-64
    • Wilcock, D.M.1    Colton, C.A.2
  • 22
    • 49049089830 scopus 로고    scopus 로고
    • Immunotherapy reduces vascular amyloid-beta in PDAPP mice
    • Schroeter S, Khan K, Barbour R, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 2008;28:6787-93
    • (2008) J. Neurosci. , vol.28 , pp. 6787-6793
    • Schroeter, S.1    Khan, K.2    Barbour, R.3
  • 23
    • 79960817113 scopus 로고    scopus 로고
    • Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's association research roundtable workgroup
    • Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Demen 2011;7:367-85
    • (2011) Alzheimers Demen. , vol.7 , pp. 367-385
    • Sperling, R.A.1    Jack Jr., C.R.2    Black, S.E.3
  • 24
    • 84863115941 scopus 로고    scopus 로고
    • Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
    • Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69:198-207
    • (2012) Arch. Neurol. , Issue.69 , pp. 198-207
    • Ostrowitzki, S.1    Deptula, D.2    Thurfjell, L.3
  • 25
    • 84855780598 scopus 로고    scopus 로고
    • Gantenerumab: A novel human anti-abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta
    • Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: A novel human anti-abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 2012;28:49-69
    • (2012) J. Alzheimers Dis. , Issue.28 , pp. 49-69
    • Bohrmann, B.1    Baumann, K.2    Benz, J.3
  • 26
    • 58149401811 scopus 로고    scopus 로고
    • Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice
    • Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci 2008;28:14156-64
    • (2008) J. Neurosci. , vol.28 , pp. 14156-14164
    • Koenigsknecht-Talboo, J.1    Meyer-Luehmann, M.2    Parsadanian, M.3
  • 28
    • 10744230547 scopus 로고    scopus 로고
    • Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization
    • Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54
    • (2003) Neurology , vol.61 , pp. 46-54
    • Orgogozo, J.M.1    Gilman, S.2    Dartigues, J.F.3
  • 29
    • 20944448555 scopus 로고    scopus 로고
    • Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial
    • Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62
    • (2005) Neurology , vol.64 , pp. 1553-1562
    • Gilman, S.1    Koller, M.2    Black, R.S.3
  • 30
    • 77951851348 scopus 로고    scopus 로고
    • Pre-dementia Alzheimer's trials: Overview
    • Aisen PS. Pre-dementia Alzheimer's trials: Overview. J Nutr Health Aging 2010;14:294
    • (2010) J. Nutr. Health Aging , vol.14 , pp. 294
    • Aisen, P.S.1
  • 31
    • 77951780844 scopus 로고    scopus 로고
    • Seeing with new eyes: Finding a path to early intervention trials in Alzheimer's disease
    • Cedarbaum JM, Crans G, Grundman M. Seeing with new eyes: Finding a path to early intervention trials in Alzheimer's disease. J Nutr Health Aging 2010;14:306-9
    • (2010) J. Nutr. Health Aging , vol.14 , pp. 306-309
    • Cedarbaum, J.M.1    Crans, G.2    Grundman, M.3
  • 33
    • 35348981740 scopus 로고    scopus 로고
    • Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide
    • Hayashi T, Shishido N, Nakayama K, et al. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic Biol Med 2007;43:1552-9
    • (2007) Free Radic. Biol. Med. , vol.43 , pp. 1552-1559
    • Hayashi, T.1    Shishido, N.2    Nakayama, K.3
  • 34
    • 35948936850 scopus 로고    scopus 로고
    • Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron
    • Nakamura M, Shishido N, Nunomura A, et al. Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry 2007;46:12737-43
    • (2007) Biochemistry , vol.46 , pp. 12737-12743
    • Nakamura, M.1    Shishido, N.2    Nunomura, A.3
  • 37
    • 33646855957 scopus 로고    scopus 로고
    • Neuropathology of Alzheimer disease: Pathognomonic but not pathogenic
    • Castellani RJ, Lee HG, Zhu X, et al. Neuropathology of Alzheimer disease: Pathognomonic but not pathogenic. Acta Neuropathol 2006;111:503-9
    • (2006) Acta. Neuropathol. , vol.111 , pp. 503-509
    • Castellani, R.J.1    Lee, H.G.2    Zhu, X.3
  • 38
    • 34248560960 scopus 로고    scopus 로고
    • Amyloid-beta in Alzheimer disease: The null versus the alternate hypotheses
    • Lee HG, Zhu X, Castellani RJ, et al. Amyloid-beta in Alzheimer disease: The null versus the alternate hypotheses. J Pharmacol Exp Ther 2007;321:823-9
    • (2007) J. Pharmacol. Exp. Ther. , vol.321 , pp. 823-829
    • Lee, H.G.1    Zhu, X.2    Castellani, R.J.3
  • 39
    • 0037264969 scopus 로고    scopus 로고
    • Therapeutic antibodies for human diseases at the dawn of the twenty-first century
    • Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003;2:52-62
    • (2003) Nat. Rev. Drug Discov. , vol.2 , pp. 52-62
    • Brekke, O.H.1    Sandlie, I.2
  • 40
    • 77953282150 scopus 로고    scopus 로고
    • A single ascending dose study of bapineuzumab in patients with Alzheimer disease
    • Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:198-203
    • (2010) Alzheimer Dis. Assoc. Disord. , vol.24 , pp. 198-203
    • Black, R.S.1    Sperling, R.A.2    Safirstein, B.3
  • 41
    • 84855854663 scopus 로고    scopus 로고
    • Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid beta monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease
    • Uenaka K, Nakano M, Willis BA, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid beta monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease. Clin Neuropharmacol 2012;35:25-9
    • (2012) Clin. Neuropharmacol. , Issue.35 , pp. 25-29
    • Uenaka, K.1    Nakano, M.2    Willis, B.A.3
  • 42
    • 19944431509 scopus 로고    scopus 로고
    • Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta
    • Racke MM, Boone LI, Hepburn DL, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005;25:629-36
    • (2005) J. Neurosci. , vol.25 , pp. 629-636
    • Racke, M.M.1    Boone, L.I.2    Hepburn, D.L.3
  • 43
    • 84863750982 scopus 로고    scopus 로고
    • Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease
    • Epub ahead of print].
    • Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer Disease. Arch Neurol 2012. [Epub ahead of print].
    • (2012) Arch. Neurol.
    • Blennow, K.1    Zetterberg, H.2    Rinne, J.O.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.